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method is useful to reveal patient preferences, and might support the development
of evidence-based and sustainable health policy on patient charges in Central-and
Eastern European countries.
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OBJECTIVES: To determine the factors associated with paediatric inappropriate
use (IU) of the accident and emergency department (A&E) METHODS: An observa-
tional prospective survey was performed. All the patients attending A&E in 12
Belgian hospitals during 2 weeks in 2010 were included. The use of A&E was con-
sidered appropriate if, at least, one of the following criteria was met: child referred
by a doctor or the police, brought by ambulance, need for a short stay[i], need for
technical examination or orthopaedic treatment, in patient admission, death.
RESULTS: The median age of the 3220 children included was 3.3 years old (0-15.9);
39.3% of the visits were not appropriate according to the definition above. Five
determinants were included in a multivariate analyze: age, having a family doctor,
night or week-end use of A&E, parents’ perception of severity for child’s illness and
insurance status. Two factors were associated with a decrease of IU: parents’ per-
ception of high severity for child’s illness (Adjusted OR 0.6; 95% IC 0.4-0.8) and
having a family doctor (Adjusted OR 0.6; 95% IC 0.4-0.9). Two other factors were
associated with an increase of IU: children age less than 2 years (Adjusted OR 1.8;
95% IC 1.5-2.2) and night or week-end use of A&E (Adjusted OR 1.4; 95% IC 1.1-1.7).
After adjustment, the insurance status has no more impact on the appropriateness
of A&E use.CONCLUSIONS: In a country like Belgium, where it is not compulsory to
be registered with a family doctor, the risk of an IU is mainly due to the failure of
outpatient care for children2 years and the use of A&E during night or weekend.
Parents’ perception of high severity for child’s health status and having a family
doctor were associated with the appropriateness of A&E use.
Health Care Use & Policy Studies – Diagnosis Related Group
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OBJECTIVES: Medical databases that contain comprehensive claims data linked to
individual patients can be an important source for the parameterization of deci-
sion-analytic models. Moreover, they are useful for preliminary studies that aim to
identify promising research questions and crucial health problems. The goal of this
research was on the one hand to analyze health care utilization of children and
adolescents using claims data of Austria’s social health insurances and on the
other hand to gain insight into the general usefulness of the data for further mod-
eling studies. METHODS: The database contains all claims data from the insured
population during two years (2006 and 2007). We selected patients who were alive
and under 20 years old on 1 January 2007. These represented the base population
for the analyses. As the database contains no medical diagnoses in ambulatory care
we used the drug prescription data and statistically identified links between ATC
codes on level 3 and ICD-9 groups (Weisser et al., 26th PCSI Conference, Munich,
2010). RESULTS: The basic population consisted of 1, 885, 037 individuals. Antiin-
fectives for system use (ATC code “J”) were by far the most prescribed drug group
with 1,231,496 prescriptions. Based on medical prescriptions 646 790 / 685,946 per-
sons were linked to acute respiratory infections in 2006 / 2007. As expected the
provider types with most consultations were general practitioners, dentists and
pediatrists. CONCLUSIONS: The first step for preinvestigation – the identification
of relevant diseases and related subpopulations – requires a linkage of reimburse-
ment claims to diagnoses (in this case via drug prescriptions). Afterwards it is
possible to analyze the health care utilization and to identify further medical
events of the subpopulation as long as all the data is linked to individuals. Our
results on child and adolescent health care utilization can point out further direc-
tions for future modeling studies.
Health Care Use & Policy Studies – Drug/Device/Diagnostic Use & Policy
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OBJECTIVES: The Spanish antidepressant market is the 7th market in volume in
Spain, and represented 475 million Euros in 2010. As a measure to contain phar-
maceutical expenditure and promote rational drug use, the Spanish Autonomous
Regions (AR) have implemented, among other policies, prescription quality indica-
tors for generics (PQIG). The objective of this study was to analyze the generic
antidepressant market in those AR with and without PQIG and to assess whether
the AR with PQIG have higher generic sales than those without indicators.
METHODS: We identified the AR with PQIG, through their health services web
pages. We obtained the sales of branded and generic antidepressants (SSRIs, NS-
MRIs, MAOIs and other antidepressants) in volume (units) for each AR for the
period 2007-2010 – data obtained from IMS Health® Regional database. Sales were
adjusted per one million population – data obtained from National Statistics Insti-
tute. From these data, we estimated generic prescription and compared growth for
the period 2007-2010. RESULTS: Nine out of the 17 AR have PQIG (Andalusia, Bale-
aric Islands, Catalonia, Castilla-La Mancha, Castilla-León, Madrid, Basque Country,
La Rioja and Valencia). Generic prescription increased 8 points from 2007 to 2010,
both groups having similar growth (8 and 7 points in the PQIG and non-PQIG group,
respectively). In 2007, the mean generic prescription in the AR with PQIG was the
14%, whereas in the non-PQIG group was 10%. In 2010, it was 22% in the AR with
PQIG and 17% in the non-PQIG ones. Andalusia and Catalonia were the AR with the
highest percentage (38% and 28%, respectively) and Murcia and Country Basque
were the lowest (11% and 14%, respectively). CONCLUSIONS: The PQIG had an
overall positive impact in generic prescription, although other factors, such as PQIG
implementation approach may influence the real impact of indicators in sales.
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OBJECTIVES: Orphan drug legislations have been introduced to encourage the de-
velopment of orphan drugs. In the European Union (EU), orphan drugs are used for
the diagnosis, prevention or treatment of life-threatening or serious conditions
that affect  5 in 10,000 people. It is estimated that approximately 7000 rare dis-
eases exist. We assessed the characteristics and outcomes of the new drug devel-
opment for rare diseases in the EU. METHODS: Data on therapeutic indications for
the cohort of orphan drugs authorised in the EU were extracted from the European
Public Assessment Reports of the European Medicines Agency (EMA) and the Eu-
ropean Commission Register of medicinal products (up to June 2011). RESULTS:
Overall, 64 orphan drugs were authorised in the EU since 2000, corresponding to a
total of 77 indications. Median time from orphan designation to EMA authorisation
was 2.6 years (P25-P75: 1.5-4.5 years). Sixty percent of the total indications were for
the treatment of rare diseases that affect  1 in 10,000 people. By therapeutic area,
the percentage of indications with a marketing authorisation was heterogenous
(e.g., 45% for malignant neoplasms, 32% for blood and endocrine disorders, 6% for
cardiovascular diseases, 6% for neurological and mental conditions, or 3% for peri-
natal conditions, among others). CONCLUSIONS: Regulatory reform efforts have
contributed to the development of orphan drugs. Further research is needed to
explain whether unmet needs are being addressed among patients with rare dis-
eases.
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OBJECTIVES: Originally intended for drug utilization studies, ATC classification is
now increasingly used worldwide as a tool for controlling prices of pharmaceutical
products. This research looked at how select markets within Europe and Latin
America have incorporated ATC classification into their pricing policies to drive
down prices of similar drugs. METHODS: The research was conducted through
in-depth secondary analysis and primary research. National and regional level
payers from 10 countries within Europe and Latin America were interviewed using
structured discussion guides to explore the role of ATC classification in their re-
spective countries. RESULTS: ATC classification is used in varying degrees to in-
form the pricing and reimbursement decision-making within the 10 countries that
were included in the study (EU5, Sweden, Denmark, Mexico, Brazil and Argentina).
In countries such as Italy and Spain, ATC 3rd and 4th level classification is an
important determinant of reimbursement status of drugs for many chronic dis-
eases. In Germany and Denmark, price comparators for a new drug are sometimes
chosen from within the 4th level ATC classification. There are exceptions to this
when it comes to biologics, innovative products and orphan drugs. In Latin Amer-
ica, ATC classification plays a less influential role in pricing and reimbursement
and is mostly used in organisation of drug lists on the national formulary.
CONCLUSIONS: ATC classification plays a significant role in many countries in
Europe as a tool for supporting pricing and reimbursement decisions. Often over-
looked, ATC classification is an important consideration for pharmaceutical com-
panies at launch when determining the price of drugs.
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OBJECTIVES: In 1992, the French law introduced a legal framework for the provi-
sion of drugs without a French market authorization (MA) for compassionate use,
called temporary use authorization (ATU). This specific French program, aimed to
facilitate early access to innovative drugs, is suspected to be inflationary as ATUs
bypass public bodies in charge of health technology assessment and of pricing.
Moreover, the national health insurance fully reimburses ATU expenditures. The
objective of this work was to explore the economic status of previous ATUs before
and after they got a MA, in regards of their clinical benefits. METHODS: A retro-
spective descriptive analysis was performed on all ATUs that obtained a French MA
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